Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • Chapter 14 - Cryopreservation of spermatozoa

  • from Section 4 - Fertility preservation strategies in the male
  • Edited by Jacques Donnez, Université Catholique de Louvain, Belgium, S. Samuel Kim, University of Kansas
  • Book: Principles and Practice of Fertility Preservation
  • Published online: 04 February 2011
  • Print publication: 03 February 2011, pp 176-198

  • Summary

    This chapter covers issues most likely to be raised by young women who have been diagnosed with breast cancer or those at high risk of the disease contemplating assisted fertility procedures. The type of adjuvant regimen selected for an individual woman is determined by menopause status, biological characteristics of the tumor and risk of relapse. Large meta-analyses of multiple trials with longterm follow-up have been used to assess the effects of systemic therapy on breast cancer outcomes. Achievement of amenorrhea appears to be associated with a reduction in relapse and improvement in survival in premenopausal women with estrogen receptor positive (ER+) tumors. There are three main barriers to implementing fertility preservation in women with breast cancer: cost; concern about treatment delays; and concern that increasing sex hormones as a result of controlled ovarian stimulation (COS) protocols will stimulate proliferation in ER+ tumors.